$VRTX
VERTEX PHARMACEUTICALS INC / MA

2020 Q1 Form 10-Q Financial Statement

#000087532020000019 Filed on May 01, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $1.515B $858.4M
YoY Change 76.5% 33.96%
Cost Of Revenue $162.5M $95.09M
YoY Change 70.88% 32.79%
Gross Profit $1.353B $763.3M
YoY Change 77.2% 34.11%
Gross Profit Margin 89.27% 88.92%
Selling, General & Admin $182.3M $147.0M
YoY Change 23.95% 13.28%
% of Gross Profit 13.47% 19.26%
Research & Development $448.5M $339.5M
YoY Change 32.12% 9.32%
% of Gross Profit 33.16% 44.47%
Depreciation & Amortization $26.82M $27.14M
YoY Change -1.18% 66.06%
% of Gross Profit 1.98% 3.56%
Operating Expenses $630.8M $486.5M
YoY Change 29.65% 10.49%
Operating Profit $720.2M $276.8M
YoY Change 160.19% 114.74%
Interest Expense $14.14M $14.87M
YoY Change -4.92% -11.95%
% of Operating Profit 1.96% 5.37%
Other Income/Expense, Net -$61.13M $42.61M
YoY Change -243.46% -56.0%
Pretax Income $657.5M $320.2M
YoY Change 105.37% 49.16%
Income Tax $54.80M $51.53M
% Of Pretax Income 8.33% 16.1%
Net Earnings $602.8M $268.6M
YoY Change 124.38% 27.76%
Net Earnings / Revenue 39.78% 31.29%
Basic Earnings Per Share $2.32 $1.05
Diluted Earnings Per Share $2.29 $1.03
COMMON SHARES
Basic Shares Outstanding 259.8M shares 255.7M shares
Diluted Shares Outstanding 263.5M shares 260.2M shares

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.190B $3.478B
YoY Change 20.47% 40.41%
Cash & Equivalents $3.593B $2.894B
Short-Term Investments $597.0M $584.0M
Other Short-Term Assets $223.0M $130.0M
YoY Change 71.54% 9.24%
Inventory $187.1M $136.7M
Prepaid Expenses
Receivables $845.3M $438.3M
Other Receivables $0.00 $0.00
Total Short-Term Assets $5.446B $4.183B
YoY Change 30.2% 37.55%
LONG-TERM ASSETS
Property, Plant & Equipment $736.3M $758.1M
YoY Change -2.87% -5.32%
Goodwill $1.002B $50.38M
YoY Change 1889.04% -0.03%
Intangibles $400.0M
YoY Change
Long-Term Investments $47.00M
YoY Change
Other Assets $160.6M $39.04M
YoY Change 311.45% 22.75%
Total Long-Term Assets $3.447B $2.079B
YoY Change 65.8% 301.71%
TOTAL ASSETS
Total Short-Term Assets $5.446B $4.183B
Total Long-Term Assets $3.447B $2.079B
Total Assets $8.893B $6.262B
YoY Change 42.02% 75.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $100.7M $82.26M
YoY Change 22.42% 11.07%
Accrued Expenses $1.258B $532.7M
YoY Change 136.19% 17.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $36.00M
YoY Change 111.76%
Total Short-Term Liabilities $1.539B $1.106B
YoY Change 39.07% 33.74%
LONG-TERM LIABILITIES
Long-Term Debt $533.0M $560.0M
YoY Change -4.82% -3.11%
Other Long-Term Liabilities $181.7M $70.23M
YoY Change 158.8% 155.72%
Total Long-Term Liabilities $181.7M $70.23M
YoY Change 158.8% 155.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.539B $1.106B
Total Long-Term Liabilities $181.7M $70.23M
Total Liabilities $2.432B $1.820B
YoY Change 33.62% 19.55%
SHAREHOLDERS EQUITY
Retained Earnings -$1.250B -$3.030B
YoY Change -58.74% -40.73%
Common Stock $7.698B $7.478B
YoY Change 2.94% 2.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.462B $4.723B
YoY Change
Total Liabilities & Shareholders Equity $8.893B $6.262B
YoY Change 42.02% 75.96%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income $602.8M $268.6M
YoY Change 124.38% 27.76%
Depreciation, Depletion And Amortization $26.82M $27.14M
YoY Change -1.18% 66.06%
Cash From Operating Activities $815.7M $324.8M
YoY Change 151.15% 28.55%
INVESTING ACTIVITIES
Capital Expenditures $19.45M $18.04M
YoY Change 7.81% -38.38%
Acquisitions
YoY Change
Other Investing Activities $51.10M -$21.10M
YoY Change -342.18% -161.7%
Cash From Investing Activities $31.67M -$39.14M
YoY Change -180.91% -893.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $300.0M $94.01M
YoY Change 219.15% 840.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$359.4M -$41.99M
YoY Change 756.01% -153.18%
NET CHANGE
Cash From Operating Activities $815.7M $324.8M
Cash From Investing Activities $31.67M -$39.14M
Cash From Financing Activities -$359.4M -$41.99M
Net Change In Cash $481.3M $243.3M
YoY Change 97.83% -28.07%
FREE CASH FLOW
Cash From Operating Activities $815.7M $324.8M
Capital Expenditures $19.45M $18.04M
Free Cash Flow $796.2M $306.7M
YoY Change 159.58% 37.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
259079000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000875320
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
VERTEX PHARMACEUTICALS INC / MA
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
258993000 shares
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
259079000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
258993000 shares
CY2019Q1 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
1500000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
-5000000 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei Entity File Number
EntityFileNumber
000-19319
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
50 Northern Avenue
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3039129
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210
CY2020Q1 dei City Area Code
CityAreaCode
617
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
341-6100
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.01 Par Value Per Share
CY2020Q1 dei Trading Symbol
TradingSymbol
VRTX
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
259276709 shares
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1515107000 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
858435000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
162497000 USD
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
95092000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
448528000 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
339490000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
182258000 USD
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
147045000 USD
CY2020Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1600000 USD
CY2019Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
794883000 USD
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
581627000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
720224000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
276808000 USD
CY2020Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
12576000 USD
CY2019Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
15615000 USD
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-14136000 USD
CY2019Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-14868000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-61130000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42610000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
657534000 USD
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
320165000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54781000 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
51534000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
602753000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
268631000 USD
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.32
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.05
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.29
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.03
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
259815000 shares
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
255695000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
263515000 shares
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
260175000 shares
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
602753000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
268631000 USD
CY2020Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-764000 USD
CY2019Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
596000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
18782000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-222000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2662000 USD
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
4967000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15356000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5341000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
618109000 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
273972000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3593412000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3109322000 USD
CY2020Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
596984000 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
698972000 USD
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
845269000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
633518000 USD
CY2020Q1 us-gaap Inventory Net
InventoryNet
187087000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
167502000 USD
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
223648000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
213515000 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
5446400000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
4822829000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
736303000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
745080000 USD
CY2020Q1 us-gaap Goodwill
Goodwill
1002158000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
1002158000 USD
CY2020Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
400000000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
400000000 USD
CY2020Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1147705000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1190815000 USD
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
160635000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
157583000 USD
CY2020Q1 us-gaap Assets
Assets
8893201000 USD
CY2019Q4 us-gaap Assets
Assets
8318465000 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
100703000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
87610000 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1258271000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1116912000 USD
CY2020Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
179776000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
130305000 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1538750000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1334827000 USD
CY2020Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
532952000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
538576000 USD
CY2020Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
178100000 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
176500000 USD
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
181745000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
183318000 USD
CY2020Q1 us-gaap Liabilities
Liabilities
2431547000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
2233221000 USD
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
2591000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
2589000 USD
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
7695905000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
7937606000 USD
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
13383000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1973000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1250225000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1852978000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6461654000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6085244000 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8893201000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8318465000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4435203000 USD
CY2019Q1 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
-40310000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5341000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
268631000 USD
CY2019Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
98007000 USD
CY2019Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
5832000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
64044000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
94243000 USD
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4723313000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6085244000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15356000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
602753000 USD
CY2020Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
300026000 USD
CY2020Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
136167000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
77594000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
116900000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6461654000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
602753000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
268631000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
115706000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
93791000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26821000 USD
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27140000 USD
CY2020Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1600000 USD
CY2019Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
CY2020Q1 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
36705000 USD
CY2019Q1 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
43425000 USD
CY2020Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-44870000 USD
CY2019Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
43551000 USD
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-9668000 USD
CY2019Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2431000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
223672000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
30136000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
27450000 USD
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
13139000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2790000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7941000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
14285000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-24145000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
153814000 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-27279000 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
57808000 USD
CY2019Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
24537000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
815698000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
324784000 USD
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
75265000 USD
CY2019Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
128215000 USD
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
60145000 USD
CY2019Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
107118000 USD
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
72036000 USD
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
0 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19450000 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18041000 USD
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5800000 USD
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31666000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39138000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
79597000 USD
CY2019Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
63620000 USD
CY2020Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
300026000 USD
CY2019Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
94007000 USD
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
136167000 USD
CY2019Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5832000 USD
CY2020Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
10287000 USD
CY2019Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
9385000 USD
CY2020Q1 vrtx Proceeds From Finance Leases
ProceedsFromFinanceLeases
5833000 USD
CY2019Q1 vrtx Proceeds From Finance Leases
ProceedsFromFinanceLeases
0 USD
CY2020Q1 vrtx Proceeds From Collaborative Funding
ProceedsFromCollaborativeFunding
2500000 USD
CY2019Q1 vrtx Proceeds From Collaborative Funding
ProceedsFromCollaborativeFunding
5000000 USD
CY2020Q1 vrtx Repaymentsof Collaborative Funding
RepaymentsofCollaborativeFunding
880000 USD
CY2019Q1 vrtx Repaymentsof Collaborative Funding
RepaymentsofCollaborativeFunding
1385000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-359430000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-41989000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-6651000 USD
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-378000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
481283000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
243279000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3120681000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2658253000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3601964000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2901532000 USD
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
13771000 USD
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
13148000 USD
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5845000 USD
CY2019Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1835000 USD
CY2020Q1 vrtx Employee Benefit Plan Payable Receivable
EmployeeBenefitPlanPayableReceivable
817000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
602753000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
268631000 USD
CY2019Q1 vrtx Employee Benefit Plan Payable Receivable
EmployeeBenefitPlanPayableReceivable
510000 USD
CY2020Q1 vrtx Accrued Share Repurchase Liability
AccruedShareRepurchaseLiability
0 USD
CY2019Q1 vrtx Accrued Share Repurchase Liability
AccruedShareRepurchaseLiability
4000000 USD
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Use of Estimates </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with (i) determining the transaction price of revenues and (ii) accounting for intangible assets and contingent consideration. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div>
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1515107000 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
858435000 USD
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
76300000 USD
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
62300000 USD
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
259815000 shares
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
255695000 shares
CY2020Q1 us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
31000 shares
CY2019Q1 us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
25000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
263515000 shares
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
260175000 shares
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.32
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.05
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.29
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.03
CY2020Q1 us-gaap Cash
Cash
1800000000 USD
CY2019Q4 us-gaap Cash
Cash
2300000000 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
176500000 USD
CY2020Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1600000 USD
CY2020Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
178100000 USD
CY2020Q1 us-gaap Cash
Cash
1800000000 USD
CY2019Q4 us-gaap Cash
Cash
2300000000 USD
CY2020Q1 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
87096000 USD
CY2020Q1 us-gaap Equity Securities Fv Ni Unrealized Gain
EquitySecuritiesFvNiUnrealizedGain
78082000 USD
CY2020Q1 us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
0 USD
CY2020Q1 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
165178000 USD
CY2020Q1 vrtx Debtand Equity Securities Cost
DebtandEquitySecuritiesCost
519163000 USD
CY2020Q1 vrtx Debtand Equity Securities Unrealized Gain
DebtandEquitySecuritiesUnrealizedGain
78837000 USD
CY2020Q1 vrtx Debtand Equity Securities Unrealized Loss
DebtandEquitySecuritiesUnrealizedLoss
1016000 USD
CY2020Q1 vrtx Debtand Equity Securities Fair Value
DebtandEquitySecuritiesFairValue
596984000 USD
CY2019Q4 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
113829000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
41833000 USD
CY2019 us-gaap Equity Securities Fv Ni Unrealized Gain
EquitySecuritiesFvNiUnrealizedGain
168255000 USD
CY2019 us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
0 USD
CY2019Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
282084000 USD
CY2019Q4 vrtx Debtand Equity Securities Cost
DebtandEquitySecuritiesCost
530216000 USD
CY2019Q4 vrtx Debtand Equity Securities Unrealized Gain
DebtandEquitySecuritiesUnrealizedGain
168811000 USD
CY2019Q4 vrtx Debtand Equity Securities Unrealized Loss
DebtandEquitySecuritiesUnrealizedLoss
55000 USD
CY2019Q4 vrtx Debtand Equity Securities Fair Value
DebtandEquitySecuritiesFairValue
698972000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2199419000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1243469000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
2157586000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1137942000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
105527000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2199419000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1243469000 USD
CY2020Q1 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 USD
CY2020Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-39400000 USD
CY2019Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
43600000 USD
CY2020Q1 us-gaap Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
22346000 USD
CY2020Q1 us-gaap Reclassification From Aoci Current Period Net Of Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
6990000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15356000 USD
CY2019Q1 us-gaap Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
10689000 USD
CY2019Q1 us-gaap Reclassification From Aoci Current Period Net Of Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
5348000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5341000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-61130000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42610000 USD
CY2020Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
24835000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
26247000 USD
CY2020Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
117427000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
107021000 USD
CY2020Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
44825000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
34234000 USD
CY2020Q1 us-gaap Inventory Net
InventoryNet
187087000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
167502000 USD
CY2020Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
1194000 USD
CY2019Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
452000 USD
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
115706000 USD
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
93791000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
115706000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
93791000 USD
CY2020Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
64246000 USD
CY2019Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
39524000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
51460000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
54267000 USD
CY2020Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5519000 shares
CY2020Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y11M23D
CY2020Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
137.34
CY2020Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3203000 shares
CY2020Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
119.05
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54800000 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
51500000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
205200000 USD
CY2020Q1 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
43000000.0 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
33900000 USD
CY2020Q1 vrtx Indemnification Claims
IndemnificationClaims
0 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3109322000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3593412000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2650134000 USD
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2893885000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3120681000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3601964000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2658253000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2901532000 USD

Files In Submission

Name View Source Status
0000875320-20-000019-index-headers.html Edgar Link pending
0000875320-20-000019-index.html Edgar Link pending
0000875320-20-000019.txt Edgar Link pending
0000875320-20-000019-xbrl.zip Edgar Link pending
a2020q110-q.htm Edgar Link pending
a2020q110-qexhibit311.htm Edgar Link pending
a2020q110-qexhibit312.htm Edgar Link pending
a2020q110-qexhibit32.htm Edgar Link pending
a2020q110-qexhibit321.htm Edgar Link pending
a2020q110-q_htm.xml Edgar Link completed
chart-46ee851a54315f11b13.jpg Edgar Link pending
chart-c6f6127e7bb55486951.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vrtx-20200331.xsd Edgar Link pending
vrtx-20200331_cal.xml Edgar Link unprocessable
vrtx-20200331_def.xml Edgar Link unprocessable
vrtx-20200331_lab.xml Edgar Link unprocessable
vrtx-20200331_pre.xml Edgar Link unprocessable